Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Patient Comfort With Vascular Closure

This study has been completed.
Sponsor:
Collaborator:
Access Pharmaceuticals, Inc.
Information provided by (Responsible Party):
University of Florida
ClinicalTrials.gov Identifier:
NCT00998023
First received: October 19, 2009
Last updated: December 5, 2011
Last verified: November 2011
Results First Received: September 21, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Vascular Closure
Interventions: Device: Mynx Vascular Closure Device
Device: AngioSeal Vascular Closure Device

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were recruited from the clinical practice of the investigator between November 2009 and July 2010.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participants who had any groin pain before placement of the closure device were excluded.

Reporting Groups
  Description
Mynx VCD Mynx Vascular Closure Device
AngioSeal VCD AngioSeal Vascular Closure Device

Participant Flow:   Overall Study
    Mynx VCD   AngioSeal VCD
STARTED   32   32 
COMPLETED   32   32 
NOT COMPLETED   0   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Mynx VCD Mynx Vascular Closure Device
AngioSeal VCD AngioSeal Vascular Closure Device
Total Total of all reporting groups

Baseline Measures
   Mynx VCD   AngioSeal VCD   Total 
Overall Participants Analyzed 
[Units: Participants]
 32   32   64 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   26   22   48 
>=65 years   6   10   16 
Gender 
[Units: Participants]
     
Female   22   19   41 
Male   10   13   23 
Region of Enrollment 
[Units: Participants]
     
United States   32   32   64 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Mean Score on the Visual Analogue Scale   [ Time Frame: Immediately before vascular closure and immediately after vascular closure. ]

2.  Secondary:   Major Complications   [ Time Frame: 1 Day ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The Angio-Seal Evolution is only one of a variety of potential vascular closure devices available on the market that would be suitable for comparison with the Mynx; however, this study was limited to just one of such alternative devices.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: J Mocco, M.D.
Organization: University of Florida
phone: 352-273-9000
e-mail: jmocco@neurosurgery.ufl.edu



Responsible Party: University of Florida
ClinicalTrials.gov Identifier: NCT00998023     History of Changes
Other Study ID Numbers: 479-2009
Study First Received: October 19, 2009
Results First Received: September 21, 2011
Last Updated: December 5, 2011
Health Authority: United States: Institutional Review Board